Good day, and welcome to the Scientific Industries Reports First Quarter of Fiscal 2023 Financial Results Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touch-tone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Mr. Joe Dorame. Please go ahead, sir. Thanks, Chuck. Good afternoon, and thank you for joining us today to review the Financial Results of Scientific Industries, Inc for the First Quarter of Fiscal Year 2023, ended September 30th, 2022. With us today on the call are Helena Santos, Chief Executive Officer, Daniel Grünes, CEO of Scientific Bioprocessing, and John Moore, Chairman. After the conclusion of today's prepared remarks, we will open the call for questions. Before we begin with prepared remarks, I would like to remind everyone, certain statements made by the management team of Scientific Industries during this conference call constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Except for the statements of historical fact, this conference call may contain forward-looking statements that involve risks and uncertainties, some of which are detailed under risk factors in documents filed by the company with the Securities and Exchange Commission, including the annual report on Form 10-K for the year ended June 30th, 2022. Forward-looking statements speak only as of the date the statements were made. The company can give no assurance that such forward-looking statements will prove to be correct. Scientific Industries does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Now I'd like to turn the call over to Helena Santos, CEO of Scientific Industries. Helena. Thank you, Joe, and welcome to our first quarter fiscal 2023 shareholder call. Our benchtop laboratory equipment operations generated $332,000 of EBITDA, and that equated to nearly $500,000 after other non-cash expenses, which are principally the stock-based compensation costs. This is despite an industry-wide slowdown related mostly to the cessation of COVID-related Vortex Genie sales. Our bioprocessing systems operations reflected a 10% lower operating loss, as disclosed in our Form 10-Q, I mean, this quarter, compared to the prior year's same quarter, primarily due to synergistic integration cost reductions as we continue to invest in the future of our company while being mindful of the bottom line. We are progressing with the post-merger restructuring of the bioprocessing operations and further grew the team by over 55%. That's 45 employees at the end of September versus 29 at the end of September of last year. We did this while reducing the operating costs, which is what led to the 10% cut in the loss. As much as possible, we will continue to look for synergies amongst our operating segments. We're delighted that the Genie product line remained a solid contributor and provides reliable cash flow for our company as we transition to our digitally simplified pharmacy and bioprocessing growth engines. I'm happy to report a substantial 75% growth in revenues of the VIVID ONE automated pill counter product and the upcoming release of the VIVID LITE. Supply chain challenges related to the components did delay the initial November launch to December, but the launch of the VIVID LITE is forthcoming. I am especially proud that we have made upgrades to the VIVID ONE that has closed the gap in speed of counting pills versus our higher-end competitive products that normally sell for 2x our list price. The VIVID ONE is built on a cloud architecture that has allowed us to upgrade about 80% of our eligible customers, this as part of our already installed base. The 48 sales reps at our distribution partner, Rx Systems in the U.S., are extremely excited by the upgraded product, as well as our roadmap for further improvements and new product releases. The VIVID LITE is a lower-priced line extension of under $4,000 compared to the mid-$5,000s for our VIVID ONE. The VIVID LITE targets more price-sensitive customers. These customers, for the most part, are currently using manual or mechanical counting processes, but who will also be required to comply in the coming year to federally mandated labeling and tracking requirements. This is referred to as GS1 codes. The good news is that our VIVID pill counter is GS1 ready and provides true track and trace, which is the whole premise of this new requirement. I would like to remind our shareholders that we have announced that we are changing our fiscal year from a June year-end to a calendar or December year-end. Therefore, we will report on a sub-period for July 2022 through December 2022. This change is part of the evolution here at our company to align with our customers' buying cycles, to align with our competitors, and to simplify internal planning as well. With that, I would like to turn it over to Daniel Grünes, our CEO of Scientific Bioprocessing. Daniel? Thank you, Helena. Hi, everyone. This recent quarter marks an important, very important milestone for the bioprocessing business as it saw the first product being launched as a joint organization. After more than two years of development, we will finally release our new software platform, which represents an important cornerstone on our roadmap towards digitally simplified bioprocessing. The DOTS software is designed for ease of customer use regarding the handling of sensors, actuators and bioprocess data, and enables the visualization, analysis and control of critical bioprocess parameters from calibration to data collection. In other words, it will help our customers connect the dots in their research, development and production. In addition, we have also launched our new DOTS PH and DO Flow Cells, as well as unlocked a new value proposition for our existing products, namely automated biomass-based feeding for feedback control in shake flasks. This feature will not only allow us to capture additional previously untapped potential from our legacy portfolio, but it's also a major step forward in showcasing our commercial vision to close the gap between shake flasks and bioreactors. I'm particularly happy about the first feedback that we received from the market and from our existing customers. From the 350 customers that we have, and the 200 of these that have a hardware that enables them to switch to the new DOTS software right away, 33 customers have already transitioned to DOTS, 27 customers are currently in the process of transitioning, and another 46 customers are on the waiting list. Essentially almost half. For the ones whose hardware is too old to transition as it is, we have further launched a promotional campaign which will allow these customers to trade in their old hardware for the most recent version and hence enter the DOTS universe as well. As you can imagine, such a launch, rollout and handover from product management and R&D after two years to marketing and sales is very comprehensive and time consuming, even more so in a quarter that usually hosts the summer break. In light of that, I'm very happy to see that we have managed to continue our commercial transition from a royalty-based business towards end user product sales. The quarter saw a 35% increase in product sales compared to the last fiscal quarter, and a 50% growth in product sales compared to the same quarter last year. At the same time, we have added important names, new names to our customer list, such as GSK, and managed to expand systems at existing customers, where we are now established not only in research, but also in tech transfer and manufacturing production. With August this quarter being the strongest sales month of our history so far at $170,000 in product sales, I'm confident that we are on a good path towards realizing our ambitious growth targets. With that, I'd like to hand it back to Helena. Thank you. Daniel. Joe? All right. Chuck, could you please provide the instructions for the listeners to ask questions? Yes, sir. If you would like to ask a question, please press star then one on your touch tone phone. If you would like to withdraw your question, please press star then two and we'll wait for a roster to assemble. Again, if you would like to ask a question, please press star then one. This concludes our question- and- answer session. I would like to turn the conference over to Mr. John Moore for any closing remarks. Please go ahead. Great. Well, thank you so much. This has been a building block quarter. We're very excited about the future. We're excited about the changes that are happening, transitioning Scientific Industries to a digitally simplified company that can provide single-use products and recurring revenues and ever greater value to our customers. Thank you so much to our shareholders for supporting us, and we're very excited about the future. Thank you very much. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.